Literature DB >> 11516477

The hyperdynamic circulation in cirrhosis: an overview.

L Blendis1, F Wong.   

Abstract

The hyperdynamic circulation begins in the portal venous bed as a consequence of portal hypertension due to the increased resistance to flow from altered hepatic vascular morphology of chronic liver disease. Dilatation of the portal vein is associated with increased blood flow, as well as the opening up or formation of veno-venous shunts and splenomegaly. At the same time, portal hypertension leads to subclinical sodium retention resulting in expansion of all body fluid compartments, including the systemic and central blood volumes. This blood volume expansion is associated with vasorelaxation, as manifested by suppression of the renin--angiotensin--aldosterone system, initially only when the patient is in the supine position. Acute volume depletion in such patients results in normalisation of the hyperdynamic circulation, whilst acute volume expansion results in exaggerated natriuresis. As liver disease progresses and liver function deteriorates, the systemic hyperdynamic circulation becomes more manifest with activation of the renin--angiotensin--aldosterone system. The presence of vasodilatation in the presence of highly elevated levels of circulating vasoconstrictors may be explained by vascular hyporesponsiveness due to increased levels of vasodilators such as nitric oxide, as well as the development of an autonomic neuropathy. However, vasodilatation is not generalised, but confined to certain vascular beds, such as the splanchnic and pulmonary beds. Even here, the status may change with the natural history of the disease, since even portal blood flow may decrease and become reversed with advanced disease. The failure of these changes to reverse following liver transplantation may be due to remodelling and angiogenesis.

Entities:  

Mesh:

Year:  2001        PMID: 11516477     DOI: 10.1016/s0163-7258(01)00124-3

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  37 in total

1.  Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.

Authors:  Mihajlo Gjeorgjievski; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2016-02-08

Review 2.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

Review 3.  Update on adrenal insufficiency in patients with liver cirrhosis.

Authors:  Anca Trifan; Stefan Chiriac; Carol Stanciu
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 4.  Renin-angiotensin system in the pathogenesis of liver fibrosis.

Authors:  Regina Maria Pereira; Robson Augusto Souza dos Santos; Filipi Leles da Costa Dias; Mauro Martins Teixeira; Ana Cristina Simões e Silva
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

5.  Doppler ultrasound of hepatic and system hemodynamics in patients with alcoholic liver cirrhosis.

Authors:  Drazen Zekanovic; Zekanovic Drazen; Neven Ljubicic; Ljubicic Neven; Marko Boban; Boban Marko; Marko Nikolic; Nikolic Marko; Diana Delic-Brkljacic; Delic-Brkljacic Diana; Petar Gacina; Gacina Petar; Ivo Klarin; Klarin Ivo; Jadranko Turcinov; Turcinov Jadranko
Journal:  Dig Dis Sci       Date:  2009-03-10       Impact factor: 3.199

6.  Increased endothelin receptor B and G protein coupled kinase-2 in the mesentery of portal hypertensive rats.

Authors:  Qing-Hong Du; Lin Han; Jun-Jie Jiang; Peng-Tao Li; Xin-Yue Wang; Xu Jia
Journal:  World J Gastroenterol       Date:  2013-04-07       Impact factor: 5.742

Review 7.  Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.

Authors:  Chantal Schlatter; Sabin S Egger; Lydia Tchambaz; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

8.  Predictors of mortality after transjugular portosystemic shunt.

Authors:  Mona Ascha; Sami Abuqayyas; Ibrahim Hanouneh; Laith Alkukhun; Mark Sands; Raed A Dweik; Adriano R Tonelli
Journal:  World J Hepatol       Date:  2016-04-18

9.  Development of hepatorenal syndrome in bile duct ligated rats.

Authors:  Regina M Pereira; Robson A S dos Santos; Eduardo A Oliveira; Virginia H R Leite; Filipi L C Dias; Alysson S Rezende; Lincoln P Costa; Luciola S Barcelos; Mauro M Teixeira; Ana Cristina Simoes e Silva
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

10.  Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver.

Authors:  Joseph P Erinjeri; Ajita Deodhar; Raymond H Thornton; Peter J Allen; George I Getrajdman; Karen T Brown; Constantinos T Sofocleous; Diane L Reidy
Journal:  Cardiovasc Intervent Radiol       Date:  2009-09-16       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.